4-Octyl itaconate alleviates dextran sulfate sodium-induced ulcerative colitis in mice via activating the KEAP1-NRF2 pathway
- PMID: 38767761
- DOI: 10.1007/s10787-024-01490-3
4-Octyl itaconate alleviates dextran sulfate sodium-induced ulcerative colitis in mice via activating the KEAP1-NRF2 pathway
Abstract
Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disease with a relapsing-remitting course. Although its etiology remains unknown, excessive oxidative stress in colon is a major intermediate factor that can promote the progression of UC. In the present study, we investigated the effect and the underlying mechanisms of 4-Octyl itaconate (OI) on dextran sulfate sodium (DSS)-induced UC in mice. Our work identified that OI alleviated the colitis by reducing the oxidative stress and the apoptosis in colon tissue, then increasing the tight junction proteins expression and in turn enhancing the intestinal barrier function, thereby creating less severe inflammatory responses. Moreover, our results demonstrated that OI reduced the Kelch-like ECH-associated protein 1 (KEAP1) expression and subsequent upregulated nuclear factor E2-related factor (NRF2) expression and its nuclear translocation which in turn induced the expression of glutathione S-transferase (GST) and NAD(P)H: quinone oxidoreductase 1 (NQO1). In addition, ML385, a NRF2 antagonist, can inhibit the protective effects of OI on UC, indicating that the role of OI in this colitis model could be dependent on the activation of KEAP1-NRF2 pathway. Notably, OI co-administration significantly enhanced the therapeutic effects of mesalazine or 1400W on UC. Collectively, itaconate may have a great potential for use in the treatment of IBD.
Keywords: 4-Octyl itaconate; Intestinal barrier; Nuclear factor E2-related factor; Oxidative stress; Ulcerative colitis.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Geniposide ameliorates dextran sulfate sodium-induced ulcerative colitis via KEAP1-Nrf2 signaling pathway.J Ethnopharmacol. 2023 Oct 5;314:116626. doi: 10.1016/j.jep.2023.116626. Epub 2023 May 13. J Ethnopharmacol. 2023. PMID: 37187359
-
α-Lipoic acid alleviates dextran sulfate sodium salt-induced ulcerative colitis via modulating the Keap1-Nrf2 signaling pathway and inhibiting ferroptosis.J Sci Food Agric. 2024 Feb;104(3):1679-1690. doi: 10.1002/jsfa.13053. Epub 2023 Nov 15. J Sci Food Agric. 2024. PMID: 37850313
-
Four-octyl itaconate activates Keap1-Nrf2 signaling to protect neuronal cells from hydrogen peroxide.Cell Commun Signal. 2018 Nov 15;16(1):81. doi: 10.1186/s12964-018-0294-2. Cell Commun Signal. 2018. PMID: 30442144 Free PMC article.
-
4-Octyl Itaconate Activates Nrf2 Signaling to Inhibit Pro-Inflammatory Cytokine Production in Peripheral Blood Mononuclear Cells of Systemic Lupus Erythematosus Patients.Cell Physiol Biochem. 2018;51(2):979-990. doi: 10.1159/000495400. Epub 2018 Nov 22. Cell Physiol Biochem. 2018. PMID: 30466076
-
Moringin alleviates DSS-induced ulcerative colitis in mice by regulating Nrf2/NF-κB pathway and PI3K/AKT/mTOR pathway.Int Immunopharmacol. 2024 Jun 15;134:112241. doi: 10.1016/j.intimp.2024.112241. Epub 2024 May 17. Int Immunopharmacol. 2024. PMID: 38761782
Cited by
-
The emerging role of oxidative stress in inflammatory bowel disease.Front Endocrinol (Lausanne). 2024 Jul 15;15:1390351. doi: 10.3389/fendo.2024.1390351. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39076514 Free PMC article. Review.
References
-
- Bambouskova M, Gorvel L, Lampropoulou V, Sergushichev A, Loginicheva E, Johnson K, Korenfeld D, Mathyer ME, Kim H, Huang LH, Duncan D, Bregman H, Keskin A, Santeford A, Apte RS, Sehgal R, Johnson B, Amarasinghe GK, Soares MP, Satoh T, Akira S, Hai T, de Guzman SC, Auclair K, Roddy TP, Biller SA, Jovanovic M, Klechevsky E, Stewart KM, Randolph GJ, Artyomov MN (2018) Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis. Nature 556(7702):501–504. https://doi.org/10.1038/s41586-018-0052-z - DOI - PubMed - PMC
-
- Bazan L, Bendas ER, El Gazayerly ON, Badawy SS (2016) Comparative pharmaceutical study on colon targeted micro-particles of celecoxib: in-vitro-in-vivo evaluation. Drug Deliv 23(9):3339–3349. https://doi.org/10.1080/10717544.2016.1178824 - DOI - PubMed
-
- Bel S, Elkis Y, Lerer-Goldstein T, Nyska A, Shpungin S, Nir U (2012) Loss of TMF/ARA160 protein renders colonic mucus refractory to bacterial colonization and diminishes intestinal susceptibility to acute colitis. J Biol Chem 287(30):25631–25639. https://doi.org/10.1074/jbc.M112.364786 - DOI - PubMed - PMC
-
- Burri E, Maillard MH, Schoepfer AM, Seibold F, Van Assche G, Riviere P, Laharie D, Manz M, Swiss Ibdnetaowgot SSoG (2020) Treatment algorithm for mild and moderate-to-severe ulcerative colitis: an update. Digestion 101(Suppl 1):2–15. https://doi.org/10.1159/000504092 - DOI - PubMed
-
- Cai C, Ma H, Peng J, Shen X, Zhen X, Yu C, Zhang P, Ji F, Wang J (2023) USP25 regulates KEAP1-NRF2 anti-oxidation axis and its inactivation protects acetaminophen-induced liver injury in male mice. Nat Commun 14(1):3648. https://doi.org/10.1038/s41467-023-39412-6 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials
Miscellaneous